Related Experiment Videos
Beta-blockade in the management of systolic dysfunction
1Department of Small Animal Clinical Sciences, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Technical Institute, Phase II Duckpond Drive, Blacksburg, VA 24061, USA. abbottj@vt.edu
The Veterinary Clinics of North America. Small Animal Practice
|August 25, 2004
Summary
Heart failure is a neuroendocrine syndrome, not just pump dysfunction. Beta-blockers (BAAs) are standard for systolic dysfunction heart failure and may benefit dogs.
Area of Science:
- Cardiology
- Neuroendocrinology
Background:
- Heart failure is increasingly recognized as a complex neuroendocrine syndrome.
- Chronic adrenergic nervous system activation contributes to heart failure pathogenesis.
- Detrimental effects of sustained adrenergic drive on myocardial function are evident.
Purpose of the Study:
- To discuss the neuroendocrine basis of heart failure.
- To highlight the role of beta-blocker agents (BAAs) in managing heart failure.
- To explore the potential application of beta-blockade in canine heart failure.
Main Methods:
- Review of current scientific literature on heart failure.
- Analysis of the role of neuroendocrine pathways in heart failure.
- Evaluation of the efficacy of beta-blocker therapy.
Main Results:
- The traditional view of heart failure as solely pump failure is outdated.
- Neuroendocrine system activation is integral to heart failure development.
- Beta-blocker agents are established therapy for human systolic heart failure.
Conclusions:
- Heart failure management should consider its neuroendocrine components.
- Beta-blocker agents offer therapeutic benefits for heart failure patients.
- Beta-blockade shows promise for managing heart failure in dogs.